Free Trial

Pyxis Oncology (PYXS) Competitors

Pyxis Oncology logo
$1.69 +0.15 (+9.74%)
(As of 12/20/2024 05:40 PM ET)

PYXS vs. CYRX, PROC, NGNE, BTMD, DSGN, VYGR, CTNM, SLRN, KMDA, and TRVI

Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Cryoport (CYRX), Procaps Group (PROC), Neurogene (NGNE), biote (BTMD), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

Pyxis Oncology vs.

Pyxis Oncology (NASDAQ:PYXS) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Pyxis Oncology has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Pyxis Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Pyxis OncologyN/A -36.22% -28.76%
Cryoport -70.08%-13.35%-6.43%

In the previous week, Pyxis Oncology had 7 more articles in the media than Cryoport. MarketBeat recorded 10 mentions for Pyxis Oncology and 3 mentions for Cryoport. Cryoport's average media sentiment score of 0.97 beat Pyxis Oncology's score of 0.42 indicating that Cryoport is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pyxis Oncology
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cryoport
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pyxis Oncology has higher earnings, but lower revenue than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pyxis Oncology$16.15M6.22-$73.79M-$1.03-1.64
Cryoport$226.11M1.72-$99.59M-$3.38-2.33

Pyxis Oncology has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Cryoport has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Cryoport received 214 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 82.35% of users gave Pyxis Oncology an outperform vote while only 65.05% of users gave Cryoport an outperform vote.

CompanyUnderperformOutperform
Pyxis OncologyOutperform Votes
28
82.35%
Underperform Votes
6
17.65%
CryoportOutperform Votes
242
65.05%
Underperform Votes
130
34.95%

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 92.9% of Cryoport shares are held by institutional investors. 9.8% of Pyxis Oncology shares are held by insiders. Comparatively, 10.1% of Cryoport shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pyxis Oncology presently has a consensus price target of $9.43, suggesting a potential upside of 457.90%. Cryoport has a consensus price target of $12.29, suggesting a potential upside of 56.31%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than Cryoport.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pyxis Oncology
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89
Cryoport
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Pyxis Oncology beats Cryoport on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYXS vs. The Competition

MetricPyxis OncologyPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$100.50M$6.57B$5.13B$9.07B
Dividend YieldN/A2.99%5.08%4.23%
P/E Ratio-1.6410.4289.5817.17
Price / Sales6.22195.801,116.12116.95
Price / CashN/A57.1642.8237.86
Price / Book0.605.094.774.78
Net Income-$73.79M$151.83M$120.15M$225.60M
7 Day Performance4.32%-2.13%-1.92%-1.23%
1 Month Performance-20.66%-3.10%11.47%3.36%
1 Year Performance1.20%11.54%30.54%16.60%

Pyxis Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYXS
Pyxis Oncology
2.1442 of 5 stars
$1.69
+9.7%
$9.43
+457.9%
-2.9%$100.50M$16.15M-1.6460Analyst Forecast
News Coverage
Positive News
High Trading Volume
CYRX
Cryoport
3.0208 of 5 stars
$7.58
-1.4%
$12.50
+64.9%
-49.8%$374.69M$226.11M-2.321,170Analyst Forecast
Gap Down
PROC
Procaps Group
0.8894 of 5 stars
$3.23
+34.0%
N/A-20.3%$364.41M$414.10M5.105,500News Coverage
High Trading Volume
NGNE
Neurogene
3.7408 of 5 stars
$24.22
+3.0%
$60.83
+151.2%
N/A$359.79M$925,000.000.0090
BTMD
biote
3.0893 of 5 stars
$6.60
+3.6%
$9.11
+38.0%
+20.8%$358.62M$193.06M24.77194Positive News
Gap Up
DSGN
Design Therapeutics
0.9221 of 5 stars
$6.29
+12.3%
$7.00
+11.3%
+143.2%$356.15MN/A-7.1840News Coverage
Positive News
VYGR
Voyager Therapeutics
4.6114 of 5 stars
$6.49
+3.5%
$17.00
+161.9%
-27.6%$354.55M$250.01M8.83100
CTNM
Contineum Therapeutics
1.9558 of 5 stars
$13.65
-2.7%
$29.25
+114.3%
N/A$351.90M$50M0.0031News Coverage
SLRN
Acelyrin
2.7884 of 5 stars
$3.38
+4.6%
$11.75
+247.6%
-55.8%$339.12MN/A-1.31135
KMDA
Kamada
3.8909 of 5 stars
$5.84
-0.5%
$14.50
+148.3%
-1.2%$335.68M$158.38M20.96360Positive News
TRVI
Trevi Therapeutics
3.0363 of 5 stars
$4.34
+4.1%
$9.31
+114.6%
+214.0%$333.62MN/A-10.2020Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:PYXS) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners